← Back to headlines
Arrowhead Pharmaceuticals Plans sNDA for SHASTA After Positive Trial Results
Arrowhead Pharmaceuticals announced plans to submit a supplemental New Drug Application (sNDA) for its drug SHASTA by the end of 2026, following trial results that showed significant triglyceride reductions and fewer pancreatitis events.
5 Aug, 00:42 — 5 Aug, 00:42
Sources
Showing 1 of 1 sources
Related Stories
Revolve and Wix Project Strong 2026 Financial Performance
23m ago
SpaceX's AI Spending and Wall Street's Insurance Takeover Raise Concerns
24m ago
Freshworks Targets Sustained GAAP Profitability with 2026 Revenue Guidance
25m ago
MasterBrand Outlines Second-Half 2026 Sales and Long-Term Leverage Targets
26m ago